"What" Series

What is Duration of Response (DoR) in Clinical Trials?

16 October 2023
2 min read

Duration of Response (DoR) is defined as the time from randomization to disease progression or death for patients who achieve complete or partial alleviation. It is closely related to Disease-Free Survival (DFS) and measures the response time of patients to treatments with no tumor growth or metastasis.

DoR is useful for assessing treatment plans with durable responses and delayed disease progression, but not useful for treatments providing temporary relief without lasting benefits.

Keep Reading
Back to all blogs →
Analysis on the Research Progress of Oncolytic virus
Advanced Tech.
6 min read
Analysis on the Research Progress of Oncolytic virus
16 October 2023
Oncolytic virus (OVs) refers to a generic name for viruses that naturally exist or are genetically edited to selectively kill tumor cells.
Read →
First participant receives Cu-67 SAR-Bombesin treatment in theranostic prostate cancer study
Latest Hotspot
3 min read
First participant receives Cu-67 SAR-Bombesin treatment in theranostic prostate cancer study
16 October 2023
Clarity Pharmaceuticals proudly announces the initial patient dosing in their 64Cu/67Cu SAR-Bombesin Phase I/II theranostic trial for patients with metastatic castrate resistant prostate cancer.
Read →
What is Duration of Clinical Benefit (DoCB) in Clinical Trials?
"What" Series
2 min read
What is Duration of Clinical Benefit (DoCB) in Clinical Trials?
16 October 2023
Duration of Clinical Benefit (DoCB) is defined as the time from randomization to disease progression or death in patients who achieve complete remission, partial remission, or disease stability for 24 weeks or longer.
Read →
REGENXBIO Reveals Clinical Information from Phase I/II Study of RGX-202
Latest Hotspot
3 min read
REGENXBIO Reveals Clinical Information from Phase I/II Study of RGX-202
16 October 2023
REGENXBIO Inc. disclosed further provisional safety information and preliminary effectiveness results from the phase I/II AFFINITY DUCHENNE™ study of RGX-202 aimed at treating Duchenne Muscular Dystrophy.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.